

Special Issue

Radiolabeled Compounds for Diagnosis and Treatment of Cancer II

Message from the Guest Editor

Significant advances in the design and evaluation of novel radiopharmaceuticals in preclinical and clinical environments have allowed for wider adoption of imaging technologies, such as SPECT and PET, and treatment of various cancers. Numerous radiopharmaceuticals have become commercially available for a range of applications, and more are undergoing development and the regulatory approval process. These radiopharmaceuticals are critical to the diagnosis and staging of diseases, as well as the selection of patients for various therapies and the monitoring of their outcomes. The editorial team of *Molecules* is developing a Special Issue titled “Radiolabeled Compounds for Diagnosis and Treatment of Cancer”, which will focus on all aspects of design, characterization, evaluation and development of novel radiolabeled compounds for the diagnosis and treatment of cancer, as well as the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Submissions—both original research papers and reviews—related to the areas mentioned above are desired.

Guest Editor

Dr. Krishan Kumar

Vaccine Translational Research Branch/VRP/DAIDS, National Institute of Allergy and Infectious Diseases (NIH), 5601 Fishers Lane, Room 9B56, Rockville, MD 20892, USA

Deadline for manuscript submissions

closed (31 October 2022)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/105374

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).